A phase-1 study of monoclonal antibody ABBV-8E12, which recognizes the N terminal region of tau, showed a favorable safety and tolerability profile in patients with progressive supranuclear palsy (PSP), a tauopathy that shares some features with AD. This evidence concerns the gene MAPT and tauopathy.